A major challenge facing global tuberculosis (TB) eradication efforts is the fact that two billion people are latently infected with Mycobacterium tuberculosis (Mtb), many of whom, especially in the setting of HIV co-infection, will develop reactivation disease. Efforts to gain insight into the molecular mechanisms by which Mtb persists in the host have been impeded by the lack of adequate research models and molecular tools. Current research has focused on identifying individual Mtb genes or host factors required for TB latency and reactivation in specific models and inferring their relevance for TB latency and reactivation in humans. The central hypothesis of this proposal is that no single host or microbial pathway is responsible for Mtb entry into or emergence from latency, but rather, that these complex phenomena are attributable to multiple interdependent host and mycobacterial molecular networks, which cannot be deduced from any one particular model. Using a systems biology approach, including several novel animal models of latent TB infection in combination with transcriptional, proteomic, genetic, imaging, and computational techniques, followed by experimental verification of the data using human samples, we will identify host cytokine networks responsible for immunological control of Mtb growth, as well as Mtb regulatory and metabolic pathways required for bacillary growth restriction and reactivation. Our data are expected to yield: 1) Novel potential drug targets for nonreplicating bacilli, with the goal of shortening the duration of TB chemotherapy;2) Novel diagnostic markers specific to the latent stage of infection and to reactivation disease;and 3) Novel attenuated vaccine candidates with an inability to reactivate, which would be particularly important in the setting of HIV/AIDS.
Antibiotic treatment for TB requires at least 6 months of therapy because the germs that cause TB can go """"""""dormant"""""""" in the infected host, becoming very difficult to kill with currently available drugs, which kill dividing bacteria. In this proposal, we plan to use a multidisciplinary approach to uncover some of the important mechanisms that lead TB germs to stop dividing and to start growing again when the immune system weakens. Our results are expected to yield new drug targets to shorten the time it takes to cure TB, as well as new vaccine candidates and diagnostic tests for different stages of the infection.
|Xu, Zhihong; Zhou, Aiping; Wu, Jiawei et al. (2018) Transcriptional Approach for Decoding the Mechanism of rpoC Compensatory Mutations for the Fitness Cost in Rifampicin-Resistant Mycobacterium tuberculosis. Front Microbiol 9:2895|
|McCarron, Pauraic; McCann, Malachy; Devereux, Michael et al. (2018) Unprecedented in Vitro Antitubercular Activitiy of Manganese(II) Complexes Containing 1,10-Phenanthroline and Dicarboxylate Ligands: Increased Activity, Superior Selectivity, and Lower Toxicity in Comparison to Their Copper(II) Analogs. Front Microbiol 9:1432|
|Chuang, Yu-Min; Dutta, Noton K; Hung, Chien-Fu et al. (2016) Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo. Antimicrob Agents Chemother 60:6460-6470|
|Dutta, Noton K; Bruiners, Natalie; Pinn, Michael L et al. (2016) Statin adjunctive therapy shortens the duration of TB treatment in mice. J Antimicrob Chemother 71:1570-7|
|Via, Laura E; Savic, Rada; Weiner, Danielle M et al. (2015) Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infect Dis 1:203-214|
|Zhou, Aiping; Ni, Jinjing; Xu, Zhihong et al. (2015) Metabolomics specificity of tuberculosis plasma revealed by (1)H NMR spectroscopy. Tuberculosis (Edinb) 95:294-302|
|Levine, David M; Dutta, Noton K; Eckels, Josh et al. (2015) A tuberculosis ontology for host systems biology. Tuberculosis (Edinb) 95:570-4|
|Xu, Zhihong; Zhou, Aiping; Ni, Jinjing et al. (2015) Differential expression of miRNAs and their relation to active tuberculosis. Tuberculosis (Edinb) 95:395-403|
|Dutta, Noton K; Karakousis, Petros C (2014) Thioridazine for treatment of tuberculosis: promises and pitfalls. Tuberculosis (Edinb) 94:708-11|
|Kana, Bavesh Davandra; Karakousis, Petros C; Parish, Tanya et al. (2014) Future target-based drug discovery for tuberculosis? Tuberculosis (Edinb) 94:551-6|
Showing the most recent 10 out of 26 publications